Stefan Gruenert

Dr. Stefan Gruenert

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2002 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
Elzbieta JandaElzbieta Janda
Elzbieta Janda
KLKerstin Lehmann
Kerstin Lehmann
IKIris Killisch
Iris Killisch
MJMartin Jechlinger
Martin Jechlinger
MHMichaela Herzig
Michaela Herzig
SGStefan Gruenert
Stefan Gruenert
Multistep carcinogenesis involves more than six discrete events also important in normal development and cell behavior. Of these, local invasion and metastasis cause most cancer deaths but are the least well understood molecularly. We employed a combined in vitro/in vivo carcinogenesis model, that is, polarized Ha-Ras–transformed mammary epithelial cells (EpRas), to dissect the role of Ras downstream signaling pathways in epithelial cell plasticity, tumorigenesis, and metastasis. Ha-Ras cooperates with transforming growth factor β (TGFβ) to cause epithelial mesenchymal transition (EMT) characterized by spindle-like cell morphology, loss of epithelial markers, and induction of mesenchymal markers. EMT requires continuous TGFβ receptor (TGFβ-R) and oncogenic Ras signaling and is stabilized by autocrine TGFβ production. In contrast, fibroblast growth factors, hepatocyte growth factor/scatter factor, or TGFβ alone induce scattering, a spindle-like cell phenotype fully reversible after factor withdrawal, which does not involve sustained marker changes. Using specific inhibitors and effector-specific Ras mutants, we show that a hyperactive Raf/mitogen-activated protein kinase (MAPK) is required for EMT, whereas activation of phosphatidylinositol 3-kinase (PI3K) causes scattering and protects from TGFβ-induced apoptosis. Hyperactivation of the PI3K pathway or the Raf/MAPK pathway are sufficient for tumorigenesis, whereas EMT in vivo and metastasis required a hyperactive Raf/MAPK pathway. Thus, EMT seems to be a close in vitro correlate of metastasis, both requiring synergism between TGFβ-R and Raf/MAPK signaling.

1 August 2003 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
SGStefan Gruenert
Stefan Gruenert
MJMartin Jechlinger
Martin Jechlinger
HBHartmut Beug
Hartmut Beug

1 June 2006 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MJMartin Jechlinger
Martin Jechlinger
ASAndreas Sommer
Andreas Sommer
RMRichard Moriggl
Richard Moriggl
PSPeter Seither
Peter Seither
NKNorbert Kraut
Norbert Kraut
SGStefan Gruenert
Stefan Gruenert
Metastasis is the major cause of cancer morbidity, but strategies for direct interference with invasion processes are lacking. Dedifferentiated, late-stage tumor cells secrete multiple factors that represent attractive targets for therapeutic intervention. Here we show that metastatic potential of oncogenic mammary epithelial cells requires an autocrine PDGF/PDGFR loop, which is established as a consequence of TGF-β–induced epithelial-mesenchymal transition (EMT), a faithful in vitro correlate of metastasis. The cooperation of autocrine PDGFR signaling with oncogenic Ras hyperactivates PI3K and is required for survival during EMT. Autocrine PDGFR signaling also contributes to maintenance of EMT, possibly through activation of STAT1 and other distinct pathways. Inhibition of PDGFR signaling interfered with EMT and caused apoptosis in murine and human mammary carcinoma cell lines. Consequently, overexpression of a dominant-negative PDGFR or application of the established cancer drug STI571 interfered with experimental metastasis in mice. Similarly, in mouse mammary tumor virus–Neu (MMTV-Neu) transgenic mice, TGF-β enhanced metastasis of mammary tumors, induced EMT, and elevated PDGFR signaling. Finally, expression of PDGFRα and -β correlated with invasive behavior in human mammary carcinomas. Thus, autocrine PDGFR signaling plays an essential role during cancer progression, suggesting a novel application of STI571 to therapeutically interfere with metastasis.

1 March 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
ARAndres Ramos
Andres Ramos
SGStefan Gruenert
Stefan Gruenert
JAJan Adams
Jan Adams
DMDavid R. Micklem
David R. Micklem
MPMark R. Proctor
Mark R. Proctor
GVGabriele Varani
Gabriele Varani
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

16 October 2003 in Oncogene
Verified
Journal Article
Closed access
MJMartin Jechlinger
Martin Jechlinger
SGStefan Gruenert
Stefan Gruenert
ITIdo H Tamir
Ido H Tamir
Elzbieta JandaElzbieta Janda
Elzbieta Janda
SLSusanna Lüdemann
Susanna Lüdemann
NKNorbert Kraut
Norbert Kraut

15 March 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
DMDavid R. Micklem
David R. Micklem
JAJan Adams
Jan Adams
SGStefan Gruenert
Stefan Gruenert
DJDaniel St Johnston
Daniel St Johnston
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.